Core Insights - 4D Molecular Therapeutics (4DMT) has published significant preclinical data demonstrating the efficacy of its proprietary Therapeutic Vector Evolution (TVE) platform and the R100 vector, which shows up to ~10-fold improvement in transduction and transgene expression compared to AAV2 in human retinal cells [1][2] - The R100 vector-based genetic medicine 4D-150 has shown promising results in nonhuman primate models for wet age-related macular degeneration (wet AMD), leading to robust expression of dual transgenes and complete suppression of severe choroidal neovascularization lesions [1][2] - Ongoing clinical trials for 4D-150 include Phase 1/2 studies for wet AMD (PRISM) and diabetic macular edema (DME) (SPECTRA), with a Phase 3 program for wet AMD expected to initiate in Q1 2025 [1][2] Company Overview - 4DMT is a clinical-stage genetic medicines company focused on developing innovative therapies for large market diseases, particularly in ophthalmology and pulmonology [8] - The company utilizes directed evolution technology to create customized AAV vectors, with R100 being a key product aimed at transforming treatment outcomes for patients with retinal diseases [3][5] - 4DMT is advancing a diverse pipeline of six clinical-stage and one preclinical product candidates targeting various diseases, including wet AMD and DME [8] Disease Context - Wet AMD has an estimated incidence rate of 200,000 new patients annually in the U.S., with a projected prevalence exceeding 4 million individuals in major markets within five years [6] - Diabetic macular edema (DME) affects approximately one million individuals in the U.S., characterized by macular swelling due to blood vessel leakage [7]

Group 1: Earnings Performance - 4D Molecular Therapeutics reported a quarterly loss of $0.79 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.67, and compared to a loss of $0.24 per share a year ago, indicating a significant decline [1] - The company posted zero revenues for the quarter ended September 2024, missing the Zacks Consensus Estimate by 99.76%, compared to revenues of $20.2 million in the same quarter last year [2] - Over the last four quarters, the company has surpassed consensus EPS estimates two times, but has not been able to beat consensus revenue estimates [2] Group 2: Stock Performance and Outlook - 4D Molecular Therapeutics shares have lost approximately 61.2% since the beginning of the year, while the S&P 500 has gained 25.5% [3] - The current consensus EPS estimate for the coming quarter is -$0.70 on $3.7 million in revenues, and for the current fiscal year, it is -$2.74 on $5.11 million in revenues [7] - The estimate revisions trend for 4D Molecular Therapeutics is mixed, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market in the near future [6] Group 3: Industry Context - The Medical - Drugs industry, to which 4D Molecular Therapeutics belongs, is currently in the top 25% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Another company in the same industry, Cosmos Health Inc., is expected to report a quarterly loss of $0.11 per share, representing a year-over-year change of -22.2%, with revenues expected to be $14 million, up 9.2% from the year-ago quarter [9]

Presented positive interim data for 4D-150 in wet age-related macular degeneration (wet AMD) from PRISM Phase 1/2 clinical trial highlighting robust and durable clinical activity across diverse patient populations and intraocular inflammation (IOI) profile numerically similar to approved anti-VEGF agents  4D-150 4FRONT Phase 3 program in wet AMD designed to maximize probability of success, continues to be on track with 4FRONT-1 trial initiation expected in Q1 2025 Continuing KOL engagement to expand awarene ...

4D Molecular Therapeutics, Inc. (FDMT) has been beaten down lately with too much selling pressure. While the stock has lost 26% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier. How to Determine if a Stock is Oversold We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a mo ...

EMERYVILLE, Calif., Sept. 23, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced a poster presentation at the 2024 North American Cystic Fibrosis Conference (NACFC) in Boston, Massachusetts on September 26-28, 2024. 2024 NACFC Poster Presentation Details: Title: Transgene expression and CFTR channel function in hu ...

4D Molecular Therapeutics, Inc. (FDMT) closed the last trading session at $15.62, gaining 6.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $50.78 indicates a 225.1% upside potential. The mean estimate comprises nine short-term price targets with a standard deviation of $17.77. While the lowest estimate of $36 indicates a 130.5% increase from the current price level, the most op ...

A downtrend has been apparent in 4D Molecular Therapeutics, Inc. (FDMT) lately with too much selling pressure. The stock has declined 21.9% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround. Here is How to Spot Oversold Stocks We use Relative Strength Index (RSI), one of the most commonly used technic ...

4D Molecular Therapeutics, Inc. (FDMT) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $0.77 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 12.50%. A quarter ago, it was expected that this company would post a loss of $0.73 per share when it actually produced a loss of $0.66, delivering a surprise of 9.59%. Over the last four quarters, the com ...

Core Insights - 4D Molecular Therapeutics has strengthened its senior management team with the appointments of Dhaval Desai as Chief Development Officer, Christopher Simms as Chief Commercial Officer, and Carlos Quezada-Ruiz as SVP, Therapeutic Area Head, Ophthalmology [1][2][3] Management Appointments - Dhaval Desai will oversee late-stage product development, medical affairs, scientific communications, regulatory, and quality operations, previously serving as SVP and Chief Development Officer at Iveric Bio [1][6] - Christopher Simms will lead pre-commercial and commercial organizations starting September 25, 2024, and has extensive experience in commercial strategy and execution from his time at Iveric Bio [1][7] - Carlos Quezada-Ruiz will head the ophthalmology franchise and manage early- and late-stage clinical development, coming from Genentech where he led clinical development for VABYSMO and SUSVIMO [1][8] Strategic Focus - The company aims to transition into Phase 3 development and pre-commercialization, focusing on large market ophthalmic diseases [3][5] - The addition of experienced leaders is expected to enhance the execution of development objectives and facilitate global regulatory submissions [3][5] Ophthalmology Advisory Board - An Ophthalmology Advisory Board has been formed, chaired by Dr. Arshad Khanani, to support development strategy and registration for large market ophthalmology programs [1][4][10] - The board includes renowned retina specialists and thought leaders, providing substantial expertise in large market ophthalmology development [5][10] Product Development and Pipeline - The company is advancing six clinical-stage and one preclinical product candidate, focusing on genetic medicines for large market diseases in ophthalmology [15] - 4D-150 is highlighted as a key product with potential for sustained efficacy and reduced treatment burden for patients [4][15]

LOS ANGELES, July 22, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D Molecular Therapeutics" or "the Company") (NASDAQ: FDMT) for violations of the securities laws. If you are a shareholder who suffered a loss, click here to participate. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder r ...